HM15211 (Hanmi Pharmaceuticals) is a triagonist with high GCG activity for obesity treatment and a balanced GLP-1 and GIP activity, to neutralize the hyperglycemic risk of GCG. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.